Search results
Nvidia Tops $1,000. Here's Why the AI Stock Was Soaring Today.
Motley Fool via Yahoo Finance· 2 days agoThe company forecast revenue of around $28 billion, ahead of the consensus at $26.4 billion and...
A Look At The Fair Value Of Titan Machinery Inc. (NASDAQ:TITN)
Simply Wall St. via Yahoo Finance· 6 hours agoThe first is the discount rate and the other is the cash flows. If you don't agree with these result...
Stock Market Today: Stocks mixed with Nvidia earnings on deck; Target plunges
TheStreet.com· 3 days agoNvidia, the market's best-performing stock over the past five years, will report fiscal-first-quarter earnings after the close of trading. Stocks finished ...
Is the Stock Market Too Concentrated?
Morningstar· 1 day agoYou surely have heard that the US stock market is too concentrated, resting its fortunes on a small number of technology stocks. Just last week, I watched ...
Stock market today: Markets on Wall Street hang near record highs as more retailers report earnings
Atlanta Journal-Constitution· 4 days agoMarkets on Wall Street were mixed early Wednesday but remain at or above record levels as more ...
Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?
InvestorPlace· 1 day agoSensei Biotherapeutics (NASDAQ:SNSE) stock is falling on Friday after it failed to impress investors...
SPCE stock analysis: Virgin Galactic has bankruptcy risks | Invezz
Invezz· 1 day agoThe Virgin Galactic (NYSE: SPCE) stock price has continued its freefall this year as concerns about...
Why Snowflake Stock Is Falling Today
Motley Fool via Yahoo Finance· 2 days ago*Stock Advisor returns as of May 13, 2024 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends...
Here's Why Ulta Beauty Is One of the Smartest Stocks to Buy on the Dip
Motley Fool via Yahoo Finance· 11 hours agoMoreover, outside of the stock market crash for the pandemic, Ulta Beauty hasn't ever...
Why Is Verastem (VSTM) Stock Down 62% Today?
InvestorPlace· 1 day agoThe company is conducting a Phase 1/2 clinical trial of avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel. The results were...
